Antengene Corporation Limited is a leading commercial-stage, R&D-driven, global biopharmaceutical company focused on the discovery, development, manufacturing and commercialization of innovative first-in- class/best-in-class therapeutics for the treatment of hematologic malignancies and solid tumors, in realizing its vision of “Treating Patients Beyond Borders”.
Antengene recently unveiled a new office space situated in Melbourne’s most sought after CBD, taking another important step in the company’s continued global expansion. The new office offers an appealing environment that will help Antengene to attract more top talents, and further accelerate its expansion in the APAC region as well as its committed efforts to bring high quality and affordable innovative medicines to patients with life-threatening conditions including hematologic malignancies and solid tumors in Asia Pacific region and around the world.
Occupying a space of 250 square meters in a Grade A office building in Melbourne’s CBD that has an impressive 4.5-star NABERS energy rating and a 5.5-star NABERS water rating, the new office provides the fast-growing Australian team a superb work environment boasting a bird view of the downtown CBD area. In addition, the office has adopted a modern design with a state-of-the-art video conferencing system to facilitate both effective communications within the local team and close collaborations with teams and partners across the globe.
Mr. Thomas Karalis, Antengene’s Corporate Vice President, Head of Asia Pacific Region, commented on the new office. “Our first dedicated Antengene office in the Asia Pacific Region is an inspiring place to work and has been embraced by our growing Antengene team. Its opening marks a significant milestone for Antengene, as it not only meets our current business needs but will also support our future growth in the APAC region and globally.”
Since 2017, Antengene has built a broad and expanding pipeline of 15 clinical and preclinical assets, of which 10 are global rights assets, and 5 came with rights for Asia Pacific markets including the Greater China region. To date, Antengene has obtained 24 investigational new drug (IND) approvals in the U.S. and Asia, and submitted 6 new drug applications (NDAs) in multiple Asia Pacific markets, with the NDA for XPOVIO® (selinexor) already approved in mainland China, South Korea, Singapore and Australia.
More information can be found on Antengene’s website, www.antengene.com.